Unmasking Fracture Risk in Type 2 Diabetes: The Association of Longitudinal Glycemic Hemoglobin Level and Medications
Open Access
- 9 December 2021
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (4) , e1390-e1401
Abstract
Context Fracture risk is underestimated in people with type 2 diabetes (T2D). Objective To investigate the longitudinal relationship of glycated hemoglobin (HbA1c) and common medications on fracture risk in people with T2D. Methods This retrospective population-based cohort study was conducted using de-identified claims and electronic health record data obtained from the OptumLabs Data Warehouse for the period January 1, 2007, to September 30, 2015. For each individual, the study was conducted within a 2-year HbA1c observation period and a 2-year fracture follow-up period. A cohort of 157 439 individuals with T2D [age ≥ 55 years with mean HbA1c value ≥ 6%] were selected from 4 018 250 US Medicare Advantage/Commercial enrollees with a T2D diagnosis. All fractures and fragility fractures were measured. Results With covariates adjusted, poor glycemic control in T2D individuals was associated with an 29% increase of all fracture risk, compared with T2D individuals who had adequate glycemic control (HR: 1.29; 95% CI, 1.22-1.36). Treatment with metformin (HR: 0.88; 95% CI, 0.85-0.92) and DPP4 inhibitors (HR: 0.93; 95% CI, 0.88-0.98) was associated with a reduced all fracture risk, while insulin (HR: 1.26; 95% CI, 1.21-1.32), thiazolidinediones (HR: 1.23; 95% CI, 1.18-1.29), and meglitinides (HR: 1.12; 95% CI, 1.00-1.26) were associated with an increased all fracture risk (All P value < 0.05). Bisphosphonates were associated similarly with increased fracture risk in the T2D and nondiabetic groups. Conclusion Longitudinal 2-year HbA1c is independently associated with elevated all fracture risk in T2D individuals during a 2-year follow-up period. Metformin and DPP4 inhibitors can be used for management of T2D fracture risk.Keywords
Funding Information
- National Institutes of Health
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R21 AR071681)
This publication has 59 references indexed in Scilit:
- Factors Associated With Poor Glycemic Control or Wide Glycemic Variability Among Diabetes Patients in Hawaii, 2006–2009Preventing Chronic Disease, 2012
- Diagnosis and Classification of Diabetes MellitusDiabetes Care, 2011
- Dipeptidyl Peptidase-4 Inhibitors and Bone FracturesDiabetes Care, 2011
- Glycemic Control, Complications, and Death in Older Diabetic PatientsDiabetes Care, 2011
- Pentosidine and Increased Fracture Risk in Older Adults with Type 2 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2009
- Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronateOsteoporosis International, 2008
- Metformin Reverts Deleterious Effects of Advanced Glycation End-Products (AGEs) on Osteoblastic CellsExperimental and Clinical Endocrinology & Diabetes, 2008
- Bone Fractures and Hypoglycemic Treatment in Type 2 Diabetic PatientsDiabetes Care, 2008
- Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug‐naïve patients with Type 2 diabetesDiabetic Medicine, 2007
- Nontraumatic Fracture Risk With Diabetes Mellitus and Impaired Fasting Glucose in Older White and Black AdultsArchives of internal medicine (1960), 2005